Skyler Jay S, Oddo Carolyn
Pediatrics & Psychology, Division of Endocrinology, University of Miami, Miami, FL 33136, USA.
Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S21-6. doi: 10.1002/dmrr.289.
In the United States (US), diabetes mellitus is a serious and costly public health problem, affecting more than 16 million people. Its incidence will continue to grow, as indicated by high rates of impaired fasting glucose levels, increased rates of obesity, and the trend toward more sedentary lifestyles. The prevalence of diabetes increases with age and varies by gender, race, and ethnicity. Diabetes also presents an enormous economic burden in the US. In 1996, total health care costs were 1 trillion dollars, 120 million dollars of which was for diabetes. A large proportion of the per-person costs associated with diabetes is for treating diabetic complications. Morbidity and mortality rates are higher in patients with diabetes than in patients without diabetes. There has been some recent improvement in type 2 diabetes treatment with the availability of newer medications, including secretagogues, metformin, acarbose, and the 'glitazones'. More patients are now using oral combination therapy, and fewer patients are using insulin. Unfortunately, many patients with type 2 diabetes are delaying the use of insulin, even when it is indicated for their treatment. Moreover, even with the new classes of oral antidiabetic agents, glycemic control remains suboptimal and patients still are not reaching the recommended target values for HbA(1c) (<7%). Primary medical care for diabetes patients is also less than optimal and must be improved. On an arbitrary gradient scale of 1 to 4 (with 1 being primitive and 4 being comprehensive), the US is only at stage 2 for diabetes care systems, indicating a pressing need for improvement in diabetes care.
在美国,糖尿病是一个严重且代价高昂的公共卫生问题,影响着超过1600万人。正如空腹血糖受损率高、肥胖率上升以及久坐不动生活方式的趋势所表明的那样,其发病率将持续增长。糖尿病的患病率随年龄增长而增加,并且因性别、种族和民族而异。糖尿病在美国还带来了巨大的经济负担。1996年,医疗保健总费用为1万亿美元,其中1.2亿美元用于糖尿病治疗。与糖尿病相关的人均费用很大一部分用于治疗糖尿病并发症。糖尿病患者的发病率和死亡率高于非糖尿病患者。随着包括促分泌剂、二甲双胍、阿卡波糖和“格列酮类”在内的新型药物的出现,2型糖尿病治疗最近有了一些改善。现在更多患者正在使用口服联合疗法,使用胰岛素的患者减少。不幸的是,许多2型糖尿病患者即使在胰岛素适用于其治疗时仍推迟使用。此外,即使有了新型口服抗糖尿病药物,血糖控制仍然不理想,患者仍未达到糖化血红蛋白(HbA1c)的推荐目标值(<7%)。糖尿病患者的初级医疗保健也不尽如人意,必须加以改善。在1至4的任意梯度量表上(1代表原始,4代表全面),美国的糖尿病护理系统仅处于第2阶段,这表明迫切需要改善糖尿病护理。